These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 14689742)

  • 1. Lipid-lowering strategies. Today's therapies and co-therapies can reduce CHD risk.
    McDonald K
    Adv Nurse Pract; 2003 Dec; 11(12):24-8; quiz 28-9. PubMed ID: 14689742
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
    Sever PS
    Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk assessment and hyperlipidemia.
    Becker J
    Crit Care Nurs Clin North Am; 2008 Sep; 20(3):277-85. PubMed ID: 18644510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments for].
    de Teresa Galván E; Jiménez Navarro M
    Rev Esp Cardiol; 1996 Jul; 49(7):483-5. PubMed ID: 8754441
    [No Abstract]   [Full Text] [Related]  

  • 5. Dietary and pharmacologic therapy of the lipid risk factors. AMA Council on Scientific Affairs.
    Conn Med; 1985 May; 49(5):321-8. PubMed ID: 3891221
    [No Abstract]   [Full Text] [Related]  

  • 6. Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction.
    Ballantyne CM
    Am Heart J; 2004 Jul; 148(1 Suppl):S3-8. PubMed ID: 15211326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).
    Albert NM; Birtcher KK; Cannon CP; Goff DC; Mulgund J; Liang L; Fonarow GC
    Am J Cardiol; 2008 May; 101(9):1242-6. PubMed ID: 18435951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [44. Normalizing blood lipids--with diet, sports and antilipemic agents].
    Faust M; Krone W
    MMW Fortschr Med; 2003 May; 145(19):I-X; quiz XI-XII. PubMed ID: 12813992
    [No Abstract]   [Full Text] [Related]  

  • 9. Reducing the risk of coronary heart disease via lipid reduction.
    Spratt KA
    J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S9-13. PubMed ID: 15467018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in current approaches to lipid lowering.
    Ansell BJ
    Am Fam Physician; 2002 Mar; 65(5):783, 786-7. PubMed ID: 11898952
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimal age for starting lipid lowering treatment. Adjusted date do not justify a lower optimal age.
    Jackson PR; Wallis EJ; Ramsay LE
    BMJ; 2000 Sep; 321(7261):637-8. PubMed ID: 11023329
    [No Abstract]   [Full Text] [Related]  

  • 12. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications.
    Chiuve SE; McCullough ML; Sacks FM; Rimm EB
    Circulation; 2006 Jul; 114(2):160-7. PubMed ID: 16818808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
    Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study.
    James P; Tan HH; MacAlpine R; Brennan G; Emslie-Smith A; Morris AD
    Diabet Med; 2004 Oct; 21(10):1108-12. PubMed ID: 15384958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hyperlipidemia].
    Bertolami V; Bertolami MC
    Arq Bras Cardiol; 1986 Feb; 46(2):73-5. PubMed ID: 3827648
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
    Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
    Scand Cardiovasc J; 2008 Aug; 42(4):279-87. PubMed ID: 18609053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences between clinical trial efficacy and real-world effectiveness.
    Davidson MH
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S405-11. PubMed ID: 17112328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evidence for lipid lowering: type 2 diabetes and coronary heart disease risk.
    Townsend D; Davis R
    Prof Nurse; 2004 Jun; 19(10):38-40. PubMed ID: 15233071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alcohol use, vascular disease, and lipid-lowering drugs.
    Kolovou GD; Salpea KD; Anagnostopoulou KK; Mikhailidis DP
    J Pharmacol Exp Ther; 2006 Jul; 318(1):1-7. PubMed ID: 16627749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.